News

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada's advocacy efforts as well as relevant developments within the government. Please note that because ALS Canada…

PrimeC, an investigational therapy by NeuroSense Therapeutics, combines two existing prescription drugs: the antibiotic ciprofloxacin and the anti‑inflammatory drug celecoxib. Together, they are thought to target three biological processes linked to ALS: inflammation in the brain, abnormal microRNA activity (small RNA molecules that help regulate…

An ALS diagnosis affects the entire family. As families adapt to changing circumstances and caregiving responsibilities, routines shift, and priorities evolve. Along the way, young people can miss out on some of the activities, friendships, and experiences that help shape…

The ALS Society of Canada (ALS Canada) is pleased to continue its collaboration with Shionogi Canada (previously Tanabe Pharma Canada) to advance excellence in ALS clinical care through The Shionogi Canada Fellowship (previously the Tanabe Pharma Canada Fellowship). This annual…

The ALS Society of Canada and the Robert Packard Center for ALS Research at Johns Hopkins are pleased to announce a collaboration to jointly fund preclinical basic science research in…

From the Research Desk highlights recent efforts from the ALS Canada Research Team, offering a window into the work made possible through your commitment to ALS research. We couldn’t do what we do without you. Thank you for your continued…

This spring, the ALS Society of Canada (ALS Canada) received two Awards of Excellence at the Gold Quill Awards, presented by the International Association of Business Communicators (IABC), recognizing work that drives meaningful engagement and action. The awards recognize the…

Tammy Moore, CEO of ALS Canada, shares a call to action in an op-ed published in The Hill Times for ALS Awareness Month, highlighting the urgent need to better understand amyotrophic lateral sclerosis (ALS) and its impact on thousands of…